From the Research
The test not primarily used for diagnosing Acute Lymphoblastic Leukemia (ALL) is Plasmaviscosity. This is because Plasmaviscosity is a test that measures the viscosity of plasma, which is not a primary diagnostic tool for ALL. The diagnosis of ALL typically relies on several specific tests including:
- Complete Blood Count (CBC) with differential
- Peripheral Blood Smear examination
- Bone Marrow aspiration and biopsy
- Flow cytometry
- Cytogenetic analysis
- Molecular testing These tests help identify the characteristic features of ALL such as increased lymphoblasts, specific immunophenotypic markers, and genetic abnormalities, as seen in studies such as 1. In contrast, Plasmaviscosity is more relevant in diagnosing and monitoring conditions that affect plasma viscosity, such as multiple myeloma or Waldenström's macroglobulinemia, and is not a key test in the diagnostic workup for ALL, as supported by the lack of mention in studies like 2, 3, and 4. Therefore, Plasmaviscosity is not a primary diagnostic test for ALL, and other tests like CBC, peripheral blood smear, bone marrow biopsy, and cytogenetic analysis are more relevant, as indicated by studies such as 5.